Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis
- Lotta, Luca A
- Sharp, Stephen J
- Burgess, Stephen
- Perry, John R. B
- Stewart, Isobel D
- Willems, Sara M
- Luan, Jian'An
- Ardanaz, Eva
- Arriola, Larraitz
- Balkau, Beverley
- Boeing, Heiner
- Deloukas, Panos
- Forouhi, Nita G
- Franks, Paul W
- Grioni, Sara
- Kaaks, Rudolf
- Key, Timothy J
- Navarro, Carmen
- Nilsson, Peter M
- Overvad, Kim
- Palli, Domenico
- Quirós, Jose Ramón
- Riboli, Elio
- Rolandsson, Olov
- Sacerdote, Carlotta
- Salamanca Fernandez, Elena
- Slimani, Nadia
- Spijkerman, Annemieke M. W
- Tjonneland, Anne
- Tumino, Rosario
- van der A, Daphne L
- van der Schouw, Yvonne T
- Mccarthy, Mark I
- Barroso, Inês
- O'Rahilly, Stephen
- Savage, David B
- Sattar, Naveed
- Langenberg, Claudia
- Scott, Robert A
- Wareham, Nicholas J.
- PANICO, SALVATORE
Publication date
January 2016
DOIAbstract
Low-density lipoprotein cholesterol (LDL-C)-lowering alleles in or near NPC1L1 or HMGCR, encoding the respective molecular targets of ezetimibe and statins, have previously been used as proxies to study the efficacy of these lipid-lowering drugs. Alleles near HMGCR are associated with a higher risk of type 2 diabetes, similar to the increased incidence of new-onset diabetes associated with statin treatment in randomized clinical trials. It is unknown whether alleles near NPC1L1 are associated with the risk of type 2 diabetes
Add to ORKG